AR060619A1 - Triazoloquinazolinonas como inhibidores de las quinasas de punto de control - Google Patents
Triazoloquinazolinonas como inhibidores de las quinasas de punto de controlInfo
- Publication number
- AR060619A1 AR060619A1 ARP070101718A ARP070101718A AR060619A1 AR 060619 A1 AR060619 A1 AR 060619A1 AR P070101718 A ARP070101718 A AR P070101718A AR P070101718 A ARP070101718 A AR P070101718A AR 060619 A1 AR060619 A1 AR 060619A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aob
- cycloalkyl
- aryl
- alkynyl
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 15
- 125000000304 alkynyl group Chemical group 0.000 abstract 12
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- -1 (C = O) aObaryl Chemical group 0.000 abstract 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 abstract 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79469406P | 2006-04-25 | 2006-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060619A1 true AR060619A1 (es) | 2008-07-02 |
Family
ID=38441857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101718A AR060619A1 (es) | 2006-04-25 | 2007-04-20 | Triazoloquinazolinonas como inhibidores de las quinasas de punto de control |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7501435B2 (OSRAM) |
| EP (1) | EP2013212A1 (OSRAM) |
| JP (1) | JP5229221B2 (OSRAM) |
| AR (1) | AR060619A1 (OSRAM) |
| AU (1) | AU2007243520B2 (OSRAM) |
| CA (1) | CA2649811A1 (OSRAM) |
| DO (1) | DOP2007000082A (OSRAM) |
| TW (1) | TW200806670A (OSRAM) |
| WO (1) | WO2007127138A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014902A (zh) * | 2005-01-06 | 2011-04-13 | 默克公司 | 检查点激酶抑制剂 |
| US7485649B2 (en) * | 2005-01-06 | 2009-02-03 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| CA2635361A1 (en) | 2006-01-04 | 2007-07-19 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| US9000027B2 (en) * | 2008-02-04 | 2015-04-07 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3 |
| WO2009102537A1 (en) * | 2008-02-14 | 2009-08-20 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| WO2010104933A1 (en) | 2009-03-11 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2800819B1 (en) * | 2012-01-06 | 2018-04-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Phosphorylation of histones and uses thereof |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| KR102875195B1 (ko) * | 2019-04-03 | 2025-10-22 | 케미테라스, 인크. | 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법 |
| TWI879771B (zh) | 2019-06-06 | 2025-04-11 | 大陸商和記黃埔醫藥（上海）有限公司 | 三環類化合物及其用途 |
| CN115197225B (zh) * | 2021-09-03 | 2023-04-11 | 贵州大学 | 一种五元杂环并喹唑啉酮类化合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1244501A (en) * | 1968-03-09 | 1971-09-02 | Aspro Nicholas Ltd | Heterocyclic amines |
| PT760819E (pt) * | 1994-05-24 | 2000-11-30 | Hoffmann La Roche | Derivado dicarbonilicos triciclicos |
| US5677309A (en) * | 1996-03-22 | 1997-10-14 | Neurogen Corporation | 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands |
| CA2519107A1 (en) * | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| HRP20130429T1 (en) * | 2005-06-10 | 2013-06-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| CA2635361A1 (en) | 2006-01-04 | 2007-07-19 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
-
2007
- 2007-04-17 TW TW096113500A patent/TW200806670A/zh unknown
- 2007-04-20 AR ARP070101718A patent/AR060619A1/es not_active Application Discontinuation
- 2007-04-20 WO PCT/US2007/009643 patent/WO2007127138A1/en not_active Ceased
- 2007-04-20 AU AU2007243520A patent/AU2007243520B2/en not_active Ceased
- 2007-04-20 CA CA002649811A patent/CA2649811A1/en not_active Abandoned
- 2007-04-20 JP JP2009507739A patent/JP5229221B2/ja not_active Expired - Fee Related
- 2007-04-20 EP EP07755786A patent/EP2013212A1/en not_active Withdrawn
- 2007-04-24 US US11/789,288 patent/US7501435B2/en not_active Expired - Fee Related
- 2007-04-25 DO DO2007000082A patent/DOP2007000082A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2649811A1 (en) | 2007-11-08 |
| DOP2007000082A (es) | 2007-12-31 |
| US20070254879A1 (en) | 2007-11-01 |
| AU2007243520B2 (en) | 2012-07-19 |
| US7501435B2 (en) | 2009-03-10 |
| EP2013212A1 (en) | 2009-01-14 |
| WO2007127138A1 (en) | 2007-11-08 |
| JP2009535334A (ja) | 2009-10-01 |
| TW200806670A (en) | 2008-02-01 |
| AU2007243520A1 (en) | 2007-11-08 |
| JP5229221B2 (ja) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060619A1 (es) | Triazoloquinazolinonas como inhibidores de las quinasas de punto de control | |
| AR064010A1 (es) | Inhibidores de la actividad de la akt | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| PE20181519A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| EA201891553A1 (ru) | Ингибиторы syk | |
| PE20150194A1 (es) | Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
| AR061844A1 (es) | Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt | |
| EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |